TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

BECLOMETHASONE DIPROPIONATE

BECLOMETHASONE DIPROPIONATE
Respiratory Approved 2025-12-16
1
Indication
--
Phase 3 Trials
0
Years on Market

Details

Status
Prescription
First Approved
2025-12-16
Routes
INHALATION
Dosage Forms
AEROSOL, METERED

Companies

Active Ingredient: BECLOMETHASONE DIPROPIONATE

BECLOMETHASONE DIPROPIONATE Approval History

Loading approval history...

What BECLOMETHASONE DIPROPIONATE Treats

1 indications

BECLOMETHASONE DIPROPIONATE is approved for 1 conditions since its original approval in 2025. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Asthma
Source: FDA Label

Drugs Similar to BECLOMETHASONE DIPROPIONATE

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

BECLOMETHASONE DIPROPIONATE FDA Label Details

Pro

Indications & Usage

Beclomethasone dipropionate HFA inhalation aerosol is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. Important Limitations of Use: Beclomethasone dipropionate HFA inhalation aerosol is NOT indicated for the relief of acute bronchospasm. Beclomethasone dipropionate HFA inhalation aerosol is a corticosteroid indicated for: Maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. Important Limitations: Not indicated for the relief of acute bronchospasm.

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.